Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has granted stock options to three newly-hired employees as part of their employment inducement. The grants, made on July 31, 2024, include options to purchase a total of 47,000 shares of Akebia's common stock at an exercise price of $1.38 per share, which matches the closing price on the grant date.
These options vest over a four-year period, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. Each option has a 10-year term and is subject to Akebia's inducement award program and specific stock option agreements.
Akebia Therapeutics (Nasdaq: AKBA), un'azienda biofarmaceutica focalizzata sulle malattie renali, ha concesso opzioni sui titoli a tre nuovi dipendenti come parte dell'induzione all'impiego. Le concessioni, effettuate il 31 luglio 2024, comprendono opzioni per acquistare un totale di 47.000 azioni delle azioni ordinarie di Akebia a un prezzo di esercizio di $1,38 per azione, che corrisponde al prezzo di chiusura alla data della concessione.
Queste opzioni maturano in un periodo di quattro anni, con il 25% che matura dopo il primo anno e il restante 75% matura trimestralmente successivamente, a condizione di continuare l'impiego. Ogni opzione ha un termine di 10 anni ed è soggetta al programma di premi di induzione di Akebia e a specifici accordi sulle opzioni azionarie.
Akebia Therapeutics (Nasdaq: AKBA), una compañía biofarmacéutica centrada en enfermedades renales, ha otorgado opciones sobre acciones a tres nuevos empleados como parte de su contratación. Las concesiones, realizadas el 31 de julio de 2024, incluyen opciones para comprar un total de 47,000 acciones de acciones ordinarias de Akebia a un precio de ejercicio de $1.38 por acción, que coincide con el precio de cierre en la fecha de concesión.
Estas opciones se consolidan durante un período de cuatro años, con un 25% consolidándose después del primer año y el 75% restante consolidándose trimestralmente a partir de entonces, condicionado a la continuidad del empleo. Cada opción tiene un plazo de 10 años y está sujeta al programa de premios de inducción de Akebia y a acuerdos específicos sobre opciones de acciones.
Akebia Therapeutics (Nasdaq: AKBA)는 신장 질환에 중점을 둔 생명공학 회사로, 새로 채용된 직원 3명에게 고용 유인을 제공하기 위해 주식 옵션을 부여했습니다. 2024년 7월 31일에 이루어진 이 부여는 Akebia의 보통주 47,000주를 주당 $1.38의 행사 가격으로 구매할 수 있는 옵션을 포함하고 있으며, 이는 부여일의 종가와 일치합니다.
이 옵션은 4년 동안 점진적으로 부여되며, 첫 해가 지나면 25%가 부여되고 이후에는 남은 75%가 분기별로 부여됩니다. 이 과정은 계속 고용 상태를 전제로 합니다. 각 옵션은 10년의 기한을 가지며, Akebia의 유인 보상 프로그램 및 특정 주식 옵션 계약의 적용을 받습니다.
Akebia Therapeutics (Nasdaq: AKBA), une société biopharmaceutique axée sur les maladies rénales, a accordé des options d'achat d'actions à trois nouveaux employés dans le cadre de leur recrutement. Les attributions, effectuées le 31 juillet 2024, comprennent des options pour acheter un total de 47 000 actions ordinaires d'Akebia à un prix d'exercice de $1,38 par action, ce qui correspond au prix de clôture à la date d'attribution.
Ces options prennent effet sur une période de quatre ans, avec 25 % prenant effet après la première année et les 75 % restants prenant effet par trimestre par la suite, conditionnel à la poursuite de l'emploi. Chaque option a une durée de 10 ans et est soumise au programme de primes d'incitation d'Akebia et à des accords spécifiques concernant les options sur actions.
Akebia Therapeutics (Nasdaq: AKBA), ein biopharmazeutisches Unternehmen, das sich auf Nierenerkrankungen konzentriert, hat drei neu eingestellten Mitarbeitern im Rahmen ihrer Anstellung Aktienoptionen gewährt. Die Zuweisungen, die am 31. Juli 2024 vorgenommen wurden, umfassen Optionen zum Kauf von insgesamt 47.000 Aktien von Akebias Stammaktien zu einem Ausübungspreis von $1,38 pro Aktie, was dem Schlusskurs am Zuweisungsdatum entspricht.
Diese Optionen werden über einen Zeitraum von vier Jahren fällig, wobei 25 % nach dem ersten Jahr und die verbleibenden 75 % danach vierteljährlich fällig werden, vorausgesetzt, die Anstellung wird fortgesetzt. Jede Option hat eine Laufzeit von 10 Jahren und unterliegt dem Anreizvergütungsprogramm von Akebia sowie spezifischen Aktienoptionsvereinbarungen.
- Akebia Therapeutics is attracting new talent with stock option incentives
- The company's stock price remained stable at $1.38 per share
- Potential dilution of existing shareholders' equity due to new stock options
The options have an exercise price of
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/akebia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302212669.html
SOURCE Akebia Therapeutics, Inc.
FAQ
How many shares of Akebia Therapeutics (AKBA) stock were granted as options on July 31, 2024?
What is the exercise price for the stock options granted by Akebia Therapeutics (AKBA) on July 31, 2024?
What is the vesting schedule for the stock options granted by Akebia Therapeutics (AKBA)?
What is the term length of the stock options granted by Akebia Therapeutics (AKBA) on July 31, 2024?
